260 related articles for article (PubMed ID: 29649003)
21. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
[TBL] [Abstract][Full Text] [Related]
22. Tumor Intrinsic PD-L1 Promotes DNA Repair in Distinct Cancers and Suppresses PARP Inhibitor-Induced Synthetic Lethality.
Kornepati AVR; Boyd JT; Murray CE; Saifetiarova J; de la Peña Avalos B; Rogers CM; Bai H; Padron AS; Liao Y; Ontiveros C; Svatek RS; Hromas R; Li R; Hu Y; Conejo-Garcia JR; Vadlamudi RK; Zhao W; Dray E; Sung P; Curiel TJ
Cancer Res; 2022 Jun; 82(11):2156-2170. PubMed ID: 35247877
[TBL] [Abstract][Full Text] [Related]
23. Cohesin-SA1 deficiency drives aneuploidy and tumourigenesis in mice due to impaired replication of telomeres.
Remeseiro S; Cuadrado A; Carretero M; Martínez P; Drosopoulos WC; Cañamero M; Schildkraut CL; Blasco MA; Losada A
EMBO J; 2012 May; 31(9):2076-89. PubMed ID: 22415365
[TBL] [Abstract][Full Text] [Related]
24. STAG Mutations in Cancer.
Romero-Pérez L; Surdez D; Brunet E; Delattre O; Grünewald TGP
Trends Cancer; 2019 Aug; 5(8):506-520. PubMed ID: 31421907
[TBL] [Abstract][Full Text] [Related]
25. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H
Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226
[TBL] [Abstract][Full Text] [Related]
26. LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL.
Parvin S; Ramirez-Labrada A; Aumann S; Lu X; Weich N; Santiago G; Cortizas EM; Sharabi E; Zhang Y; Sanchez-Garcia I; Gentles AJ; Roberts E; Bilbao-Cortes D; Vega F; Chapman JR; Verdun RE; Lossos IS
Cancer Cell; 2019 Sep; 36(3):237-249.e6. PubMed ID: 31447348
[TBL] [Abstract][Full Text] [Related]
27. The Use of Laser Microirradiation to Investigate the Roles of Cohesins in DNA Repair.
Kong X; Ball AR; Yokomori K
Methods Mol Biol; 2017; 1515():227-242. PubMed ID: 27797083
[TBL] [Abstract][Full Text] [Related]
28. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
[TBL] [Abstract][Full Text] [Related]
29. Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.
Smith MA; Hampton OA; Reynolds CP; Kang MH; Maris JM; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Wu J; Kurmasheva RT; Wheeler DA; Houghton PJ
Pediatr Blood Cancer; 2015 Jan; 62(1):91-8. PubMed ID: 25263539
[TBL] [Abstract][Full Text] [Related]
30. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
31. PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas.
Czyż M; Toma M; Gajos-Michniewicz A; Majchrzak K; Hoser G; Szemraj J; Nieborowska-Skorska M; Cheng P; Gritsyuk D; Levesque M; Dummer R; Sliwinski T; Skorski T
Oncotarget; 2016 Nov; 7(46):75551-75560. PubMed ID: 27705909
[TBL] [Abstract][Full Text] [Related]
32. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
33. Synthetic lethality of cohesins with PARPs and replication fork mediators.
McLellan JL; O'Neil NJ; Barrett I; Ferree E; van Pel DM; Ushey K; Sipahimalani P; Bryan J; Rose AM; Hieter P
PLoS Genet; 2012; 8(3):e1002574. PubMed ID: 22412391
[TBL] [Abstract][Full Text] [Related]
34. Poly (ADP-ribose) polymerase inhibitors selectively induce cytotoxicity in TCF3-HLF-positive leukemic cells.
Piao J; Takai S; Kamiya T; Inukai T; Sugita K; Ohyashiki K; Delia D; Masutani M; Mizutani S; Takagi M
Cancer Lett; 2017 Feb; 386():131-140. PubMed ID: 27894958
[TBL] [Abstract][Full Text] [Related]
35. A new thermosensitive smc-3 allele reveals involvement of cohesin in homologous recombination in C. elegans.
Baudrimont A; Penkner A; Woglar A; Mamnun YM; Hulek M; Struck C; Schnabel R; Loidl J; Jantsch V
PLoS One; 2011; 6(9):e24799. PubMed ID: 21957461
[TBL] [Abstract][Full Text] [Related]
36. CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions.
Zimmermann M; Murina O; Reijns MAM; Agathanggelou A; Challis R; Tarnauskaitė Ž; Muir M; Fluteau A; Aregger M; McEwan A; Yuan W; Clarke M; Lambros MB; Paneesha S; Moss P; Chandrashekhar M; Angers S; Moffat J; Brunton VG; Hart T; de Bono J; Stankovic T; Jackson AP; Durocher D
Nature; 2018 Jul; 559(7713):285-289. PubMed ID: 29973717
[TBL] [Abstract][Full Text] [Related]
37. Cohesin subunit RAD21: From biology to disease.
Cheng H; Zhang N; Pati D
Gene; 2020 Oct; 758():144966. PubMed ID: 32687945
[TBL] [Abstract][Full Text] [Related]
38. Cohesin SA2 is a sequence-independent DNA-binding protein that recognizes DNA replication and repair intermediates.
Countryman P; Fan Y; Gorthi A; Pan H; Strickland E; Kaur P; Wang X; Lin J; Lei X; White C; You C; Wirth N; Tessmer I; Piehler J; Riehn R; Bishop AJR; Tao YJ; Wang H
J Biol Chem; 2018 Jan; 293(3):1054-1069. PubMed ID: 29175904
[TBL] [Abstract][Full Text] [Related]
39. Cohesin gene mutations in tumorigenesis: from discovery to clinical significance.
Solomon DA; Kim JS; Waldman T
BMB Rep; 2014 Jun; 47(6):299-310. PubMed ID: 24856830
[TBL] [Abstract][Full Text] [Related]
40. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
